Drug Trial News

RSS

Newer atypical antipsychotic medications no better than older drug in treating child and adolescent schizophrenia

Two newer atypical antipsychotic medications were no more effective than an older conventional antipsychotic in treating child and adolescent schizophrenia and may lead to more metabolic side effects, according to a new study funded by the National Institutes of Health's National Institute of Mental Health (NIMH).

15 Sep 2008

Investigational drug shows promise in ovarian cancer

An investigational drug that combats ovarian cancer by inhibiting the formation of new blood vessels has shown promise in a phase II trial, according to a presentation at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm.

15 Sep 2008

DNA vaccine developed at the Karmanos Cancer Institute fights HER2-positive cancers

Researchers at the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine have developed a HER2 DNA vaccine that has shown to be effective on drug resistant tumors in mice. The study was reported in the September 15 issue of Cancer Research, a journal of the American Association for Cancer Research.

15 Sep 2008

Adding Taxotere to chemotherapy regimen improves survival in early breast cancer

For patients with early stage breast cancer that has spread to the lymph nodes, adding four cycles of docetaxel (Taxotere) into a sequential regimen of epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) reduces the risk of recurrence and death, updated long-term results show.

15 Sep 2008

Significant benefits in non-small-cell lung cancer from customizing erlotinib treatment

Lung cancer patients whose tumors carry specific genetic mutations can achieve significantly longer survival when treated with targeted therapies such as erlotinib, Spanish researchers report.

15 Sep 2008

Phase I trial for new tuberculosis vaccine

This week, a new vaccine "VPM1002" has entered the clinical phase I trial in Neuss, Germany, where it is being tested for safety on voluntary subjects. VPM1002 is based on a vaccine that has been in use since 1921, and has been genetically engineered to prevent infection with tuberculosis bacteria much more effectively than its predecessor.

11 Sep 2008

Naltrexone-derived pyridomorphinan shows promise for treatment of alcoholism

Southern Research Institute and Gallo Research Center today announced that peer-reviewed results from a study testing Naltrexone-derived pyridomorphinan (SoRI-9409) will be published in the December 2008 issue of the journal Biological Psychiatry.

11 Sep 2008

New drug promises once-a-day treatment for asthma and hay fever

The drug RPL554 apparently has the potential to effectively treat the respiratory diseases but without many of the side-effects most currently available drugs produce.

10 Sep 2008

New drug hope for cystic fibrosis patients

A science conference in the UK has heard some good news which offers hope to cystic fibrosis (CF) patients worldwide.

10 Sep 2008

Receptor activation protects retina from diabetes destruction

A drug known for it pain-relieving power and believed to stimulate memory appears to prevent this retinal damage that leads to vision loss, researchers say.

9 Sep 2008

New drug hope for cystic fibrosis patients

A new drug therapy may represent a tremendous step forward in the treatment of some 70,000 cystic fibrosis (CF) patients worldwide, Dr David Sheppard from the University of Bristol told an audience at the BA Festival of Science in Liverpool today [9 September].

9 Sep 2008

New treatment for diabetics identified

Some of the most serious health complications associated with diabetes could be prevented or delayed by taking a widely available cholesterol-lowering drug which has already been on the market for three decades, new research has shown.

8 Sep 2008

Once a week treatment for type 2 diabetes in the pipeline

Canadian researchers have found that a weekly treatment for type 2 diabetes has proved safe and effective for patients.

8 Sep 2008

Trial demonstrates safety and efficacy of neurally acting anti-migraine agent for treatment of acute migraine

CoLucid Pharmaceuticals, Inc., an innovative biotechnology company focusing on therapies for central nervous system disorders, announced Phase II results of its lead compound COL-144 in the treatment of acute migraine. Results demonstrated that COL-144 was safe and effective in relieving migraine headaches.

7 Sep 2008

Trastuzumab-DM1 - a 'smart bomb' for breast cancer treatment

Sarah Cannon Research Institute (SCRI) investigators have found that "smart bomb" therapies are effective in treating breast cancer patients while minimizing side effects.

7 Sep 2008

Antisoma commences phase II trial of AS1411 in metastatic renal cell carcinoma

Cancer drug developer Antisoma plc today announced that it has started a phase II study of AS1411 in metastatic renal cell carcinoma (kidney cancer).

4 Sep 2008

Second phase 3 trial of Bronchitol in cystic fibrosis sufferers begins

Pharmaceutical company Pharmaxis today announced that it has enrolled the first subject into its second pivotal Phase 3 clinical trial evaluating Bronchitol in cystic fibrosis sufferers.

4 Sep 2008

Clinical trial advances cystic fibrosis therapy

Axentis Pharma AG has initiated a clinical phase IIa trial to assess the safety and tolerability of a new therapeutic formulation for the treatment of severe pulmonary infection in cystic fibrosis patients. The new formulation allows an established therapeutic agent to be delivered directly to the site of infection. The forthcoming trial will also compare the effects of two different doses of the new drug.

4 Sep 2008

Diffusion Pharmaceuticals initiates phase I/II clinical trial in patients with peripheral arterial disease

Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing new drugs for the treatment of unmet medical needs, announced today that it has begun to enroll patients in a Phase I/II clinical trial of its lead drug candidate trans sodium crocetinate (TSC).

3 Sep 2008

Further analysis from ATHENA study showed Multaq (Dronedarone) reduced risk of stroke in patients with atrial fibrillation

The results of a post-hoc analysis of the data from the ATHENA study were presented today at the clinical trial update session of the European Society of Cardiology congress 2008, in Munich, Germany.

3 Sep 2008